Tab%25252525252525252525252525252525252525252525252525252525252525252520voihep

# Tab%25252525252525252525252525252525252525252525252525252525252525252520voihep ## Overview Tab%25252525252525252525252525252525252525252525252525252525252525252520voihep is a nucleoside analog used in the treatment of chronic hepatitis B virus (HBV) infection. It inhibits viral DNA polymerase, reducing viral replication. ## Primary Indications * Chronic hepatitis B virus (HBV) infection in adults and pediatric patients. ## Adult Dosing The recommended dose is typically 0.5 mg orally once daily. ## Pediatric Dosing * For patients aged 12 years and older and weighing at least 35 kg: 0.5 mg orally once daily. * Dosing for pediatric patients younger than 12 years or weighing less than 35 kg is not established. ## Dose Adjustments * **Renal Impairment:** Dose adjustment is required based on the calculated creatinine clearance (CrCl). * CrCl 30-49 mL/min: 0.5 mg every 48 hours. * CrCl 10-29 mL/min: 0.5 mg every 72 hours. * CrCl < 10 mL/min or on hemodialysis: 0.5 mg every 7 days or after hemodialysis. * **Hepatic Impairment:** No dose adjustment is typically required for mild to moderate hepatic impairment. Data in severe hepatic impairment is limited. ## Contraindications * Hypersensitivity to Tab%25252525252525252525252525252525252525252525252525252525252525252520voihep or any of its excipients. ## Adverse Effects * **Common:** Headache, nausea, fatigue, dizziness, diarrhea, abdominal pain, insomnia. * **Serious:** Lactic acidosis, severe hepatomegaly with steatosis, exacerbation of hepatitis B upon discontinuation, renal impairment. ## Key Drug Interactions * **Lactic Acidosis Risk:** Concomitant use with other drugs known to cause lactic acidosis (e.g., other nucleoside reverse transcriptase inhibitors) may increase this risk. * **Renal Impairment:** Drugs affecting renal function may alter Tab%25252525252525252525252525252525252525252525252525252525252525252520voihep levels and vice versa. ## Monitoring * **Hepatitis B viral DNA (HBV DNA) levels:** Regularly monitor viral load to assess treatment efficacy. * **Liver function tests (LFTs):** Monitor ALT, AST, bilirubin, and albumin. * **Renal function:** Monitor serum creatinine and electrolytes, especially in patients with pre-existing renal disease or those taking concomitant nephrotoxic agents. * **Lactate levels:** Consider monitoring in patients with risk factors for lactic acidosis. * **Signs and symptoms of lactic acidosis and severe hepatomegaly.** ## Clinical Pearls * Discontinuation of Tab%25252525252525252525252525252525252525252525252525252525252525252520voihep may lead to severe exacerbation of hepatitis B. Gradual withdrawal with close monitoring is recommended, particularly in patients with decompensated liver disease. * Ensure adequate contraception for both male and female patients of reproductive potential during treatment and for a specified period after discontinuation, as per prescribing information. * Long-term efficacy and safety data continue to be evaluated. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and your healthcare provider for diagnosis, treatment, and management of your condition.